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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.025Both epigenetic silencing and genetic deletion of tumor suppressors contribute to the development and
progression of breast cancer. SOX7 is a transcription factor important to development, and its down-
regulation has been reported in tumor tissues and cell lines of prostate, colon, and lung cancers.
However, the regulation of SOX7 expression and its functional role in breast cancer have not been
reported. The current study demonstrates that SOX7 mRNA and protein expression are down-regulated
in breast cancer tissues and cell lines compared with adjacent normal tissues and nontumorigenic cells,
respectively. The SOX7 promoter is hypermethylated in breast cancer cell lines compared with non-
tumorigenic cells, and the inhibition of DNA methylation increases SOX7 mRNA levels. With shRNA-
mediated SOX7 silencing, nontumorigenic immortal breast cells display increased proliferation,
migration, and invasion and form structures that resemble that of breast cancer cells in a three-
dimensional culture system. Conversely, ectopic SOX7 expression inhibits proliferation, migration,
and invasion of breast cancer cells in vitro and tumor growth in vivo. Importantly, we discovered that
SOX7 transcript levels positively correlated with clinical outcome of 674 breast cancer patients. Overall,
our data suggest that SOX7 acts as a tumor suppressor in breast cancer. SOX7 expression is likely
regulated by multiple mechanisms and potentially serves as a prognostic marker for breast cancer
patients. (Am J Pathol 2013, 183: 1645e1653; http://dx.doi.org/10.1016/j.ajpath.2013.07.025)Supported in part by Research Scholars grant 116403-RSG-09-082-01-
MGO from the American Cancer Society and grant 5R01CA106314
(G.S.); National Cancer Institute training grant 5T32CA079448 (D.B.S.);
and contract DE-AC02-05CH11231 from the Ofﬁce of Science, Ofﬁce of
Biological and Environmental Research, US Department of Energy. The
Cell & Virus Vector Core Laboratory and the Tumor Tissue Core Labo-
ratory at the Comprehensive Cancer Center of Wake Forest University
School of Medicine are supported by National Cancer Institute Cancer
Center Support grant P30CA012197.The Sex-determining region Y-box (SOX) family comprises
>20 transcription factors that are divided into subfamilies A
through H based on their conserved structural motifs. The
founding member of the SOX family, Sex-determining re-
gion Y (Sry), is the premiere sex-determining factor in male
development.1,2 SOX proteins share homologic features
with Sry both within and outside their high-mobility group
domain that recognizes and binds DNA at the SOX con-
sensus site of 50-ATATCAAAT-30.3
Historically appreciated for their role in development,
various SOX proteins are becoming increasingly recognized
as important players in the genesis and progression of human
cancers.4 SOX7, a member of subgroup F along with SOX17
and SOX18, has been reported to regulate hematopoiesis
and cardiogenesis.5e8 As a developmental regulator, SOX7
has more recently been demonstrated to regulate vascu-
lar endothelial cadherin expression during hematopoieticstigative Pathology.
.development, which implicates its role in human cancers.9
Indeed, SOX7 down-regulation has been observed in
tumors of the colon, prostate, and lung.10e13 Furthermore,
SOX7 overexpression suppressed cell proliferation and
colony formation in prostate and colon cancer cell lines and
induced apoptosis in colon cancer cells.10,12 Consistently,
SOX7 silencing has been attributed to its hypermethylation in
tumors, and this effect correlated with poor prognosis in
Stovall et almyelodysplastic syndrome patients.14 The p38 mitogen-
activated protein kinase signaling pathway has also been
reported to regulate SOX7. Mitogen-activated protein kinase
signalingeregulated transcription factors c-fos and c-jun up-
regulated SOX7 promoter activity in a reporter assay.15
Although the precise molecular mechanism by which
SOX7 exerts its tumor suppressive effects has yet to be
deﬁnitively determined, SOX7 has been reported to interact
with b-catenin and inhibit cell proliferation mediated by
WNT signaling pathways.8,10,16
The SOX7 gene is located on the p arm of human chro-
mosome 8 at a locus frequently lost in breast tumors.17 In
addition, signiﬁcant down-regulation of the SOX7 mRNA
was reported in a group of nine primary breast cancers.16 In
this study, we investigated the mechanisms of SOX7 down-
regulation and demonstrated its tumor suppressive role in
breast cancer and positive correlation with favorable clinical
outcome of breast cancer patients.
Materials and Methods
Antibodies and DNA Vectors for Gene Expression and
Knockdown
The antibodies, their catalog numbers, and the vendors used
in this study are SOX7 (AF2766; R&D Systems, Minne-
apolis, MN), Ezh2 (AC22; Cell Signaling Technology,
Beverly, MA), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (10R-G109A; Fitzgerald Industries International,
Acton, MA), b-actin (MAB1501; Chemicon International,
Temecula, CA), DNA methyltransferase 1 (DNMT1) (5032;
Cell Signaling Technology), and Ki-67 (sp6; NeoMarkers
Inc., Fremont, CA).
We used our previously described lentiviral vector pSL5
with a puromycin selection marker to express any inserted
cDNA under the control of the chicken b-actin promoter.18,19
For inducible SOX7 expression, we generated the pTetOn-7
vector using a minimal cytomegalovirus promoter to drive
cDNA expression with six copies of tetracycline-response
element upstream of the promoter. The chicken b-actin
promoter drives expression of the advanced reverse tetra-
cycline response element (Clontech Laboratories, Inc.,
Mountain View, CA) and a puromycin selection gene.
shRNAs were designed based on previously published
methods.20e22 The target sequences included a scrambled
control (50-GGGACTACTCTATTACGTCATT-30), human
SOX7 (50-GGAATGTTCACTGACGTCTT-30), humanEZH2
(50-GGTGATCACAGGATAGGTATT-30), and human
DNMT1 (50-GGATGAGAAGAGACGTAGAGTT-30).
Cell Culture, Lentiviral Production, and Infection
Human mammary epithelial cells (HMECs), nontumor-
igenic MCF-10A, and tumorigenic MCF-7, MDA-MB-231,
SK-BR-3, ZR-75-1, BT-474, BT-549, CAMA-1, HS-578T,
and SUM159PT breast cells were cultured according to the1646protocol of the ATCC (Manassas, VA) or cited literature.
Immortalized, nontumorigenic 184B5 breast cells were ge-
nerated and cultured as previously described.23,24
Lentivirus was produced by transfecting 293FT cells with
a plasmid encoding the lentivirus and three packaging
plasmids (pMDLg/pRRE, pVSV-G, and pRSV-REV) using
the calcium phosphate precipitation method.20,25 Cells were
infected with concentrated lentivirus and incubated 6 hours
with 8 mg/mL of hexadimethrine bromide (Polybrene)
before reverting to normal medium. Cells were subjected to
antibiotic selection for at least 48 hours after infection
before further studies.
Proliferation, Migration, Invasion, and
Three-Dimensional Matrigel Assays
We performed WST-1, migration, invasion, and three-
dimensional Matrigel assays as previously described.26 In
these assays, cells were infected by lentivirus expressing
either shRNAs or cDNAs. For inducible SOX7 expression,
we ﬁrst generated clonal MDA-MB-231 cell lines stably
expressing advanced reverse tetracycline response element
and then infected them with pTetOn-7 lentivirus carrying
Dox-inducible SOX7 cDNA.
Xenograft Study
We performed the xenograft study in athymic nude mice
according to a protocol approved by the Institutional Animal
Care and Use Committee of Wake Forest Health Sciences.
MDA-MB-231 cells (4  106) carrying Dox-inducible
SOX7 were injected subcutaneously into the mammary fat
pads of 8- to 10-week-old female athymic nude mice at two
sites per mouse. Mice were supplied with either 2.0 mg/mL
of Dox in their drinking water or normal water (nZ 5 mice
per group). Tumors were measured twice weekly using
a Vernier caliper, and tumor volumes were calculated using
the following formula: V Z 0.5 (Length  Width).27
Four weeks after implantation, all mice were sacriﬁced,
and xenografts were isolated, weighed, and analyzed by
Western blot analysis.
Methylation Analysis
Patient samples were acquired from the Advanced Human
Tissue Bank at Wake Forest Health Sciences and handled
according to a protocol approved by the institutional review
board of Wake Forest Health Sciences. Genomic DNA
(gDNA) from human tissues and cell lines was isolated and
converted using the EZ DNA Methylation Kit (D5001;
Zymo Research, Irvine, CA). The methylation status of the
SOX7 promoter in these gDNA samples was determined by
methylation-speciﬁc PCR according to a published proce-
dure.10 PCR was performed using Taq Polymerase (Zymo
Research) under the following parameters: 95C for 10
minutes; 35 cycles of 95C for 30 seconds, 54C or 58Cajp.amjpathol.org - The American Journal of Pathology
Figure 1 SOX7 is down-regulated in breast cancer. A: Western blot
analyses of SOX7, DNMT1, and GAPDH expression in normal, non-
tumorigenic, and tumorigenic breast cell lines. B: RT-qPCR analyses of SOX7
mRNA levels in breast cell lines. Data represent the means  SD. C:
Analyses of SOX7 transcript levels in samples from invasive ductal carci-
nomas (n Z 42) and normal adjacent tissues (n Z 143) of patients from
the GSE10780 data set. *P < 0.05, compared with HMECs.
SOX7 Tumor Suppressor in Breast Cancerfor 30 seconds, and 72C for 30 seconds; and 72C for 7
minutes.
To study the effects of methyltransferase inhibition on
SOX7 mRNA levels in MCF-7 and MDA-MB-231 cells, we
treated cells with 1 mmol/L 5-aza-20-deoxycytidine for 72
hours. Other drugs used to determine the effects of inhib-
iting histone deacetylase or histone methyltransferase
activity included 400 nmol/L Trichostatin A (TSA) for 24
hours and 3 mmol/L BIX01294 for 72 hours, respectively.
RT-qPCR Analysis
Total cellular RNA was extracted using the TRIzol protocol
(Invitrogen) and subsequently analyzed by quantitative RT-
PCR (RT-qPCR). SOX7mRNA levels were determined using
1 mg of RNA that was incubated with 0.5 mg/mL of oligo dT
primer (Promega Corp., Madison, WI) at 70C for 5 minutes.
Meanwhile, we prepared the reverse transcription mix and left
it at room temperature until the annealing step was complete.
The reverse transcription mix was immediately added and
incubated at 40C for 1 hour: 5 mL of 5 Moloney murine
leukemia virus buffer, 5mLof 10mmol/L deoxyribonucleotide
triphosphate, 0.6 mL of ribonuclease inhibitor (RNasin;
Promega Corp.), 1 mL of reverse transcriptase, and 13.4 mL of
nuclease-free water. Quantitative PCR analysis using Taqman
gene expression arrays was then performed for SOX7 expres-
sion, and data were normalized to GAPDH levels and deter-
mined by the DDCT method (Applied Biosystems Inc., Foster
City, CA).28 All analyses were performed using the ABI7000
Sequence Detection System (Applied Biosystems).
Half-Life of SOX7 Study
Experiments were performed as described previously.29 To
test the effects of variousmutations on SOX7protein stability,
we infected MDA-MB-231 cells with lentivirus expressing
the pSL5 vector or pSL5/SOX7. Cells were treated with 60
mg/mL of cycloheximide for the indicated time points.
Lysates were collected and analyzed by Western blot.
Statistical Analysis
Data in RT-qPCR, invasion,WST-1, and xenograft assays are
indicated as means  SD. Comparisons between two groups
for a single parameter were performed using Student’s t-test.
All analyses were performed using commercially available
software (SigmaPlot version 11.0; Systat Software Inc., San
Jose, CA; and Microsoft Excel 2010; Microsoft, Redmond,
WA).A differencewas considered statistically signiﬁcant atP
< 0.05.
Results
Down-Regulation of SOX7 in Breast Cancer
Previous reports suggested reduced SOX7 expression in
prostate, lung, and colon cancers.10e13 To determine itsThe American Journal of Pathology - ajp.amjpathol.orgexpression in breast cancer, we ﬁrst evaluated SOX7 mRNA
and protein levels in a panel of breast cell lines. Using
Western blot analysis and RT-qPCR, we found that both
SOX7 protein and mRNA were down-regulated in nearly all
breast cancer cell lines compared with normal ﬁnite-lifespan
HMECs and nontumorigenic, immortal MCF-10A and
184B523,24 breast cell lines (P < 0.05) (Figure 1, A and B).
Previous studies suggested that SOX7 promoter methylation
contributes to its reduced expression.10,12,14 We also ob-
served DNMT1 up-regulation in several breast cancer cell
lines relative to normal or nontumorigenic breast cells
(Figure 1A).
We next analyzed SOX7 mRNA levels in human breast
tumors from the GSE1078030 data set. SOX7 transcript levels
were markedly decreased in 42 invasive ductal carcinoma
tissues compared with 143 normal tumor-adjacent tissues
from 90 patients (PZ 1.64 1016) (Figure 1C). These data
suggest a consistent and frequent down-regulation of SOX7
expression in human breast cancer cell lines and tumors.1647
Stovall et alRegulation of SOX7 in Breast Cancer
Previous studies suggest that promoter methylation is an
important mechanism of SOX7 down-regulation in pros-
tate and colon cancers.10e12,14 Thus, we tested the meth-
ylation status of the SOX7 promoter in breast cancer using
methylation-speciﬁc PCR as described previously.10
Although normal or nontumorigenic HMECs, MCF-10A
cells, and 184B5 breast cells24 did not have detectable
methylation, we observed SOX7 promoter methylation in
six of nine breast cancer cell lines (Figure 2A). These data
suggest that methylation is a common mechanism of SOX7
silencing in breast cancer cell lines.
To determine whether DNA methylation plays a role in
reduced SOX7 expression in breast cancer, we treated MCF-7
and MDA-MB-231 cells with 5-aza-20-deoxycytidine,
a DNMT inhibitor. As shown in Figure 2B, this treatment
led to a signiﬁcant increase of SOX7 transcript levels in both
cell lines (P < 0.05). To further investigate the role of
DNA methylation in SOX7 down-regulation, we infected
MCF-7 and MDA-MB-231 cells with lentivirus expressing
an shRNA speciﬁc to DNMT1 or an scrambled control
(shCont) and analyzed SOX7 mRNA levels at 1 and 21648weeks after infection. SOX7 mRNA levels were signiﬁcantly
increased in MDA-MB-231, but not MCF-7 cells, 1 week
after infection; however, both cell lines had signiﬁcantly
elevated SOX7 mRNA levels after 2 weeks (Figure 2C).
DNMT1 knockdown was validated by RT-qPCR analyses
(Figure 2C).
To determine whether SOX7 promoter methylation occurs
in the tumors of human breast cancer patients, we analyzed
the gDNA from 27 frozen breast tumor tissues and their
matched adjacent normal tissues. Among these samples, we
clearly observed SOX7 promoter methylation in ﬁve tumor
samples (19%) (samples 1, 3, 4, 5, and 23) (Figure 2D and
Supplemental Figure S1A). Interestingly, we also detected
weak signal of the methylation in two tumor-adjacent
normal samples (patients 1 and 26). To examine whether
this standard PCR condition was too stringent, thus causing
the relatively low detection of SOX7 promoter methylation
compared with previous reports in other cancers,10,12,14 we
reduced the annealing temperature from 58C to 54C and
repeated the methylation-speciﬁc PCR for samples 6, 8, 9,
16, and 17. With this reduced stringency, we found that
most normal samples, as well as MCF-10A cells, became
positive in the PCR using the methylation-speciﬁc primersFigure 2 The SOX7 promoter is hyper-
methylated in human breast cancer cells and
tumors. A: gDNA from breast cell lines was analyzed
by methylation-speciﬁc PCR using primers speciﬁc
for the unmethylated (U) or methylated (M) SOX7
promoter. Tumorigenic breast cell lines with SOX7
promoter methylation are indicated by open
arrowheads. B: RT-qPCR analyses of MCF-7 and
MDA-MB-231 cells treated with dimethyl sulfoxide
(DMSO) or 1 mmol/L 5-aza-20-deoxycytidine (5-
Aza) for 72 hours. Data represent the means  SD
from two experiments. C: RT-qPCR analyses of
MCF-7 and MDA-MB-231 cells infected with lenti-
virus expressing either a DNMT1-speciﬁc shRNA or
shCont. Data represent the means  SD. D:
Methylation-speciﬁc PCR of gDNA from human
breast tumor (T) samples or their matched adjacent
normal (N) tissues as described in A. Patients are
deidentiﬁed as numbers 1 through 10, with MCF-
10A and MCF-7 indicated as negative and positive
controls, respectively. Samples with SOX7 promoter
methylation in tumor and tumor-adjacent normal
samples are indicated by open and closed arrow-
heads, respectively. E: RT-qPCR analysis of SOX7
levels in six patient samples from D. Data represent
the means  SD. *P < 0.05.
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the annealing temperature could produce false-positive
results.
To determine whether the methylation status of the SOX7
promoter correlated with its transcription in human tumors,
we compared SOX7 mRNA levels of six tumor samples
with their matched normal tissue. We observed SOX7
mRNA down-regulation in all tumor samples regardless of
their promoter methylation status (Figure 2E).
The relatively infrequent promoter methylation of SOX7
compared with that in prostate10 and colon12 cancer and its
consistently low mRNA expression suggest that additional
epigenetic mechanisms or gene deletion is involved in SOX7
down-regulation in human breast tumors. To determine
whether histone deacetylation contributes to inhibiting
SOX7 expression in breast cancer cells, we treated MCF-7
and MDA-MB-231 cells with 400 nmol/L TSA, an inhib-
itor of histone deacetylases, and analyzed SOX7 transcript
levels after 24 hours. Interestingly, TSA signiﬁcantly
increased SOX7 transcript levels in MCF-7 cells but had an
opposite effect on MDA-MB-231 cells (P < 0.05)
(Supplemental Figure S2A). To determine whether histone
methylation contributes to SOX7 silencing, we studied the
effects of inhibiting the methylation of histone H3 lysine 9
and histone H3 lysine 27, two well-characterized marks of
gene repression, on SOX7 transcription. The treatment of
BIX01294, an inhibitor of methyltransferases mediating
histone H3 lysine 9 methylation, did not affect SOX7 tran-
scription in MCF-7 cells but modestly decreased that in
MDA-MB-231 cells (Supplemental Figure S2A). In addi-
tion, we used two shRNAs (shEZH2-1 and shEZH2-2) to
silence EZH2, a methyltransferase catalyzing histone H3Figure 3 Effects of SOX7 knockdown on mammary cells. A: Western blot an
expressing SOX7-speciﬁc shRNA (shSOX7) or shCont. B: WST-1 proliferation assays
of four shSOX7 clones and two shCont clones. C: Representative images of a woun
the scratch and 2 days after. The dashed lines mark the edges. D: Boyden chamber
of incubation. Data were derived from two individual experiments, and each had tr
MCF-10A cells in three-dimensional Matrigel. MCF-7 cells were used as a control.
The American Journal of Pathology - ajp.amjpathol.orglysine 27 methylation. Surprisingly, EZH2 knockdown in
both MCF-7 and MDA-MB-231 cells apparently further
reduced SOX7 mRNA levels, instead of increasing it
(Supplemental Figure S2B), without causing any detectable
change in SOX7 protein levels (Supplemental Figure S2C).
We further explored SOX7 ubiquitination in mammary
cells. To determine whether protein ubiquitination contrib-
utes to SOX7 degradation, we scanned the SOX7 amino
acid sequence for potential ubiquitination sites using the
CKSAAP_UbSite Prediction software31 and found three
potential ubiquitination lysines (39, 148, and 159). However,
replacing these lysine residues with arginines did not extend
the half-life of ectopically expressed SOX7 proteins in
MDA-MB-231 cells (Supplemental Figure S3A). Consis-
tently, treatment of MDA-MB-231 cells with two different
proteasome inhibitors, MG-132 and AdaAhx3L3VS,
32 did
not lead to detectable SOX7 accumulation (Supplemental
Figure S3B), suggesting that proteasome-mediated de-
gradation is unlikely a major mechanism of SOX7 down-
regulation.
Effects of Manipulated SOX7 Expression in Breast Cell
Lines
To study the effects of SOX7 depletion in nontumorigenic
immortal breast cell lines, we stably infected MCF-10A and
184B5 cells with lentivirus expressing shCont or a SOX7-
speciﬁc shRNA (shSOX7) and generated clonal cells from
each. SOX7 knockdown was validated by Western blot
analysis (Figure 3A). We assessed the cell proliferation of
the 184B5 clones using WST-1 assays and observed a
signiﬁcantly increased mean proliferation rate in thesealyses of SOX7 in MCF-10A and 184B5 cells after infection with lentivirus
of 184B5 shCont and shSOX7 clones. Data represent the mean proliferation
d-healing assay of 184B5 cells expressing shCont and shSOX7 at the time of
invasion assays of 184B5 cells expressing shCont and shSOX7 after 48 hours
iplicate samples. E: Effects of SOX7 silencing on the morphologic features of
*P < 0.05.
1649
Figure 4 Effects of ectopic SOX7 expression on
breast cancer cells. A: Western blot analyses of
doxycycline (Dox)einducible SOX7 in MDA-MB-231
cells cultured in the absence and presence of 1.0
mg/mL of Dox for 24 hours. B: WST-1 proliferation
assays of MDA-MB-231 cells with Dox-inducible
SOX7. Data were derived from triplicate samples.
C: Representative images of wound-healing assays
of MDA-MB-231 cells with Dox-inducible SOX7.
Images were taken at the time of the scratch and
after 24 hours. The dashed lines mark the edges. D:
Boyden chamber invasion assays of MDA-MB-231
cells with Dox-inducible SOX7 incubated for 48
hours. Data were derived from two individual
experiments with triplicate samples in each. E:
Weekly tumor volumes of mouse xenografts derived
from MDA-MB-231 cells with Dox-inducible SOX7.
The mice received either regular drinking water or
water with 2.0 mg/mL of Dox. F: Xenograft tumor
weights described in E at 4 weeks. G: Immuno-
histochemical staining to detect SOX7 expression
and Ki-67 in xenografts. No 1st Ab indicates the
control without any primary antibody. Scale barZ
100 mm. *P < 0.05, **P < 0.01.
Stovall et alSOX7-depleted clones compared with that of the cells that
expressed shCont (P < 0.05) (Figure 3B). Similar results
were observed in MCF-10A cells (data not shown).
Furthermore, SOX7 depletion in 184B5 cells enhanced their
migration in wound-healing assays (Figure 3C) and
increased their invasiveness in Boyden chamber assays (P <
0.01) (Figure 3D) compared with the control cells. SOX7
knockdown was routinely validated in the cells used in these
assays.
MCF-10A cells form polarized acinar structures when
cultured in a three-dimensional Matrigel system, but this
ability is lost when the cells are transformed by proliferative
genes, such as ERBB2 and YY1.19,26 To study whether SOX7
depletion altered the morphologic features of MCF-10A
cells, we cultured MCF-10A cells that expressed shCont
and shSOX7 in the three-dimensional Matrigel system.26
Although the cells with shCont generated well-shaped
acini, SOX7 silencing by shSOX7 caused the MCF-10A
cells to form irregular clusters (Figure 3E), suggesting that1650SOX7 depletion caused a loss of polarity in this three-
dimensional culture system that resembles the morphologic
features of tumorigenic MCF-7 cells.
To study the effect of ectopic SOX7 expression on breast
cancer cells, we generated doxycycline-inducible SOX7-
expressing MDA-MB-231 cells and veriﬁed SOX7 induc-
tion (Figure 4A). Ectopic SOX7 signiﬁcantly reduced cell
proliferation in WST-1 proliferation assays (P < 0.01)
(Figure 4B), inhibited cell migration in wound-healing
assays (Figure 4C), and reduced cell invasion in Boyden
chamber assays (P < 0.05) (Figure 4D). To investigate the
effects of ectopic SOX7 expression on breast tumor growth
in vivo, inducible SOX7-expressing MDA-MB-231 cells
were subcutaneously implanted into mammary fat pads of
athymic nude mice at two sites per mouse. Mice received
either normal drinking water or water containing 2.0
mg/mL of doxycycline. Tumor volumes were signiﬁcantly
decreased in doxycycline-treated mice throughout the study
(P < 0.01) (Figure 4E). Tumors from doxycycline-treatedajp.amjpathol.org - The American Journal of Pathology
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0.01) (Figure 4F). We previously demonstrated that doxy-
cycline treatment alone did not affect the xenograft tumor
growth in athymic nude mice.19 Immunohistochemical
studies found that the mice supplied with regular water were
SOX7 negative in their xenograft tumors, whereas the miceFigure 5 SOX7expression correlateswith clinical outcomes inbreast cancer
patients.A: Breast cancer patients (nZ 759) from an international metacohort
(BrCa759) were grouped into four quartiles based on their SOX7 transcript levels
within their tumors. Shaded regions deﬁne the interquartile ranges. Themidline
of each rectangle marks the median value. T-bars extending from the inter-
quartile rangemark theﬁfth and95th percentiles; outliers are indicated by ﬁlled
circles. B: Correlation between SOX7 expression and the distant metastasis-free
survival (DMFS) by Kaplan-Meier analysis. C: Relative SOX7 mRNA levels among
different breast cancer subtypes (basal, HER2-enriched, LumA and LumB) when
compared with normal-like subtype with favorable prognosis. ***P < 0.001,
****P < 0.0001. LumA, luminal A; LumB, luminal B.
The American Journal of Pathology - ajp.amjpathol.orgwith doxycycline-containing water had positive SOX7
staining (Figure 4G). In addition, Ki-67 staining was mark-
edly stronger in these SOX7-negative tumors (no doxycy-
cline) than the tumors expressing induced SOX7 (with
doxycycline) (Figure 4G). These results suggest that ec-
topic SOX7 reduced cell proliferation in these xenograft
tumors, consistent with the in vitro data in Figure 4B. The
doxycycline-induced SOX7 expression in these tumors
was also veriﬁed by Western blot analyses (Supplemental
Figure S4).
SOX7 Expression Correlates with Clinical Outcome in
Breast Cancer Patients
In vitro and in vivo results strongly suggested a tumor
suppressive function of SOX7 in breast cancer. To examine
the clinical relevance of this discovery, we analyzed SOX7
expression in an international metacohort (BrCa759) that
consisted of six microarrays with data from 759 breast
cancer patients.33 The SOX7 intensity detected by the two
probes 224013_s_at and 228698_at in these arrays was
highly correlated (Pearson correlation coefﬁcient Z 0.69)
(Supplemental Figure S5); thus, we used their mean inten-
sity as a measure of SOX7 mRNA levels in these patients.
Because 674 patients in this metacohort had at least 5
years of follow-up after operations, we grouped them into
four quartiles based on their SOX7 transcript levels
(Figure 5A). Patients in quartiles 1 and 2 with lower SOX7
expression had a signiﬁcantly decreased distant metastasise
free survival compared with the patients in quartiles 3 and 4
with higher SOX7 expression (Figure 5B), suggesting that
SOX7 down-regulation correlated with poor clinical out-
comes of breast cancer patients. We also compared the
relative SOX7 transcript levels for ﬁve different breast cancer
subtypes among all 759 patients. As shown in Figure 5C,
SOX7 mRNA levels were signiﬁcantly decreased in patients
of more aggressive breast cancer subtypes (eg, basal, Her2
positive, LumA and LumB) when compared with those with
more indolent disease (ie, normal-like; P < 0.0001)
(Figure 5C).Discussion
We discovered SOX7 down-regulation in breast cancer cell
lines and tumors and explored the mechanisms underlying
its reduced expression. Functional studies suggested a tumor
suppressive role of SOX7 in breast cancer both in vitro and
in vivo. Importantly, we revealed a positive correlation
between SOX7 expression and clinical outcomes of breast
cancer patients. On the basis of these data, we conclude
that SOX7 acts as a tumor suppressor in breast cancer
pathogenesis.
A karyotype analysis indicated that MCF-10A cells
contain an additional chromosome 8 derivative with struc-
tural abnormalities in these cells, which may at least partially1651
Stovall et alcontribute to their high SOX7 expression.34 Nonetheless,
SOX7 expression in breast cancer cell lines remained
markedly reduced when compared with two other non-
tumorigenic normal ﬁnite or immortalized breast cells
(Figure 1, A and B). Promoter methylation has been sug-
gested as a major mechanism of SOX7 down-regulation in
human cancers.10,12,14 Consistently, we detected SOX7
promoter methylation in six of nine breast cancer cell lines.
However, although we clearly detected SOX7 promoter
methylation in some human breast cancer samples, the
frequency (5 of 27) was relatively low compared with that in
prostate and colon cancers.10,12,14 We predict that several
reasons may contribute to these observations. First, breast
cancers have high heterogeneity, and SOX7 promoter meth-
ylation may occur in some tumor cells or at speciﬁc stages of
tumor progression. Thus, the tumor sections used for gDNA
extraction could have various relative portions with SOX7
promoter methylation. Second, the ampliﬁed region of the
methylation-speciﬁc PCR contains multiple cytosine resi-
dues that may be differentially, but not necessarily simulta-
neously, methylated. Thus, the PCR primer set that was
designed to detect the completely unmethylated or methyl-
ated sequences, respectively, would not be able to generate
signals from the samples with partially methylated SOX7
promoter. Future studies using DNAmethylation sequencing
should more conclusively determine the methylation status of
the SOX7 promoter in breast cancer. Third, the down-
regulation of SOX7 in breast cancer is likely mediated by
additional mechanisms to promoter methylation.
Pharmacologic and shRNA-mediated inhibition of
DNMT1 restored SOX7 mRNA but not protein levels in
multiple breast cancer cell lines (Figure 2B and data not
shown). These results suggest that additional regulatory
mechanisms are involved in reducing SOX7 in breast
cancer. Further studies excluded the contribution of histone
deacetylation, histone H3 lysine 9 and histone H3 lysine 27
methylation, and protein ubiquitination to SOX7 down-
regulation. Unexpectedly, EZH2 knockdown apparently
further reduced SOX7 mRNA levels, which is likely an
indirect effect on SOX7 expression. At this point, we cannot
exclude the possibility that other histone modiﬁcations,
including methylation at other residues, are involved in
inhibiting SOX7 expression. Furthermore, regulation of
SOX7 mRNA stability or translation rate, such as by miRNAs,
can also play a role in this process, and these hypotheses
deserve further investigation.
The SOX7 gene is located on the p arm of chromosome 8
that is frequently deleted in cancers,17 which may at least
partially contribute to SOX7 down-regulation in breast
cancer. On the basis of currently available literature, SOX7
homozygous deletion in cancers is rare. In the current study,
the PCR ampliﬁcation of the SOX7 promoter in breast
cancer samples always revealed positive detection for either
the methylated or unmethylated form. However, we cannot
conclude that the tumor samples in this study did not
contain any SOX7 homozygous deletion, although the SOX71652gene is only approximately 7.7 kb in length. This is because
stromal or other nonneoplastic cells could contribute to the
positive PCR reading when the unmethylated primers were
used. In addition, PCR ampliﬁcation would not be able to
detect any minor mutation or deletion of the SOX7 gene
outside the primer binding regions that could genetically
diminish SOX7 expression.
Although Guo et al10 demonstrated SOX7 promoter
methylation in prostate cancer xenografts, to our knowledge
we are the ﬁrst to demonstrate tumor suppressive effects
of SOX7 in vivo for any cancer. The precise molecular
mechanism by which SOX7 antagonizes tumor growth
remains unclear, in part because of its understudied tran-
scriptional targets. In murine F9 embryonal carcinoma cells,
SOX7 activates transcription of the basement membrane
component laminin-a1 and competes with GATA-4 to
activate ﬁbroblast growth factor 3.35,36 However, these
genes are not antiproliferative; thus, SOX7-mediated tran-
scription in cancers warrants further study. Multiple reports
indicate that SOX7 interacts with and inhibits b-catenin
in colorectal cancers with frequently altered WNT sig-
naling,10,12,37 indicating that the tumor suppressive function
of SOX7 may be, at least in part, mediated by its activities
independent of its DNA-binding ability.
Collectively, data suggest that SOX7 down-regulation is
likely regulated by multiple gene expression mechanisms in
breast cancer. SOX7 acts as a tumor suppressor and has
a great potential to serve as a prognostic marker for breast
cancer patients. Future efforts should endeavor to elucidate
mechanisms behind SOX7-mediated tumor suppression,
including its transcriptional targets and its tumor-speciﬁc
down-regulation.
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